AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9287228
Drug: Indinavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (800 mg every eight hours) and Zidovudine-Lamivudine (200 mg and 150 mg respectively)
Trial: 8296259
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (200 micrograms inhaled)
Trial: 3090216
Drug: D‐xylose absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐xylose absorption
Trial: 26848517
Drug: Guided seven‐week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided seven‐week online Acceptance and Commitment Therapy (iACT) intervention
Trial: 21137291
Drug: Curving sheath‐needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curving sheath‐needle multi‐direction rotating injection (CSNMRI) with ozone
Trial: 21137291
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection method with ozone
Trial: 17331708
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with medium chain triglycerides (MG)
Trial: 17331708
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with isopropyl myristate (IPM)
Trial: 17331708
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with light liquid paraffin (LP)
Trial: 12136372
Drug: HRT containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT containing 2 mg estradiol valerate and 250 microg levonorgestrel
Trial: 10652728
Drug: 9 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 MIU (33 micrograms) of n‐hIFN beta by subcutaneous route, three times per week, on alternate days, during one year
Trial: 10652728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for the first 6 months, then switched to n‐hIFN beta treatment for the following 6 months)
Trial: 10652728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (after switching to treatment)
Trial: 2096405
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine 48 mg/70 kg
Trial: 2096405
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine 96 mg/70 kg
Trial: 282906
Drug: Cyclic administration
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic administration of arabinosyl cytosine and vincristine plus prednisone
Trial: 282906
Drug: Cyclic administration
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic administration of arabinosyl cytosine plus thioguanine plus daunomycin
Trial: 21681619
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived stem cell (BMC) therapy
Trial: 18496303
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg/kg at induction with morphine
Trial: 18496303
Drug: Morphine only
RxNorm normalized name: Morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine only (Control)
Trial: 16275797
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (amantadine hydrochloride or oseltamivir phosphate)
Trial: 7486094
Drug: Ketorolac 1
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1 mg/kg IV
Trial: 31085219
Drug: CytoSorb hemoadsorption
RxNorm normalized name: DRESSING,CUTISORB ULTRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoSorb hemoadsorption therapy
Trial: 29057795
Drug: Piceatannol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piceatannol (20 mg/day)
Trial: 27137718
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg opicapone
Trial: 16283320
Drug: 880 IU
RxNorm normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 880 IU vitamin D plus 1 g calcium carbonate
Trial: 12043851
Drug: Budesonide Turbuhaler,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Turbuhaler, 100 microg twice‐daily (b.i.d.)
Trial: 7789372
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for acute myocardial infarction in patients aged ≤ 40 years
Trial: 7789372
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for acute myocardial infarction in patients aged > 40 years
Trial: 2189246
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mefloquine + sulfadoxine + pyrimethamine (MSP)
Trial: 2189246
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose of MSP (10 mg/kg M + 20 mg/kg S + 1.0 mg/kg P)
Trial: 494166
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential calf compression
Trial: 29075107
Drug: Aerosolized hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized hyaluronan (HA), 150 kDa, administered for 2 weeks
Trial: 23463769
Drug: Bear bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bear bile capsule and Huangqi granule daily (Group B)
Trial: 23463769
Drug: Massaging the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massaging the children's parotid region and melting vitamin C in their mouth daily (Group A)
Trial: 23463769
Drug: Massages and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massages and vitamin C as prescribed in Group A, and traditional Chinese medicine as prescribed in Group B (Group C)
Trial: 9638315
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole daily
Trial: 15087692
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole daily
Trial: 11304654
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) concurrently with meals
Trial: 11304654
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) 2 hours after meals
Trial: 9484361
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg/day for 5 days, then 0.4 g/kg every 2 months for 2 years)
Trial: 9484361
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) treatment and Placebo
Trial: 8306818
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g) administered 30 min preoperatively
Trial: 8306818
Drug: Mezlocillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (2 g) and oxacillin (1 g) administered over 24 h (3 injections)
Trial: 30993478
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC)
Trial: 27234569
Drug: Acceptance Commitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance Commitment Therapy-based group intervention delivered via videoconferencing in six 90 min group sessions
Trial: 20939985
Drug: Normal control
RxNorm normalized name: Precision, Normal Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal control group (no treatment)
Trial: 20939985
Drug: Normal mice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal mice (no treatment)
Trial: 12432437
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered intravenously (IV)
Trial: 12432437
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered subcutaneously (SC)
Trial: 2176097
Drug: 1% lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine, 3 mg/kg, diluted with physiological saline solution (pH = 6.63 +/‐ 0.05)
Trial: 2176097
Drug: 1% lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine, 3 mg/kg, diluted with 1.4% sodium bicarbonate (pH = 7.34 +/‐ 0.05)
Trial: 20182846
Drug: Manganese chloride
RxNorm normalized name: Manganese Chloride
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manganese chloride tetrahydrate (Bothdel Oral Solution 10) (MCT)
Trial: 20182846
Drug: No agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No agent
Trial: 16122538
Drug: Dual-focus schema
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-focus schema therapy (DFST)
Trial: 18202666
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day for 12 weeks
Trial: 13130405
Drug: Intranasal mupirocin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin; specific dosage and duration not mentioned.
Trial: 10836915
Drug: Trimethoprim-sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160 mg or 800 mg)
Trial: 1505371
Drug: Amoxicillin/clavulanate (500/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (500/125 mg three times daily)
Trial: 28654918
Drug: tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 5 mg b.i.d.
Trial: 28654918
Drug: tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 10 mg b.i.d.
Trial: 19951447
Drug: Piperacillin/tazobactam (recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (recommended dose)
Trial: 17535624
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate 200 mg TDS for 2 weeks pre-operatively
Trial: 20124051
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron therapy
Trial: 8035916
Drug: IV penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV penicillin G (3 g q 6 h)
Trial: 8035916
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (200 mg q 24 h)
Trial: 28422462
Drug: Oral-B 7000
RxNorm normalized name: POLYETHYLENE GLYCOL 7000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B 7000 with CrossAction brush head (OCA)
Trial: 26463446
Drug: Standard corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard corticosteroid therapy (SCT) and hyperbaric oxygen (HBO) therapy without rTMS.
Trial: 23628132
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU vitamin D3 weekly for 8 weeks
Trial: 23628132
Drug: Multivitamin supplement
RxNorm normalized name: Vi-Daily Multivitamin Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplement containing 400 IU vitamin D3/d
Trial: 11720431
Drug: Paclitaxel formulated
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel formulated in Cremophor EL 15 ml m(‐2)
Trial: 3295122
Drug: Methylprednisolone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (500 mg)
Trial: 21206418
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 14 days
Trial: 21206418
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid and amoxicillin 1 g bid for 7 days, followed by metronidazole 500 mg bid, tetracycline 500 mg qid, and lansoprazole 30 mg bid for an additional 7 days
Trial: 17460497
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (12.5 mg zinc sulfate tablet daily for about 6 months)
Trial: 11956122
Drug: Moxonidine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine SR 1.5 mg BID
Trial: 11956122
Drug: Moxonidine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine SR (0.3, 0.6, 0.9, 1.2, or 1.5 mg BID)
Trial: 378733
Drug: Phenylpropanolamine 50
RxNorm normalized name: phenylpropanolamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine 50 mg
Trial: 378733
Drug: Phenylpropanolamine 100
RxNorm normalized name: guaifenesin-phenylpropanolamine 100 mg-20 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine 100 mg
Trial: 31693078
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy
Trial: 31693078
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of DAPT followed by 12 months of aspirin monotherapy
Trial: 28577272
Drug: ADV6209 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV6209 (15 mg, oral)
Trial: 28577272
Drug: Midazolam hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam hydrochloride intravenous solution (5 mg, i.v.)
Trial: 25813411
Drug: Thrice-daily (TID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily (TID) U‐500R insulin
Trial: 25813411
Drug: Twice-daily (BID)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily (BID) U‐500R insulin
Trial: 23816977
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 20% hydroxypropyl‐β‐cyclodextrin (2‐HPβCD) in a polyethylene glycol (PEG) formulation, applied twice daily for 6 months.
Trial: 23816977
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control (PEG formulation without 2‐HPβCD), applied twice daily for 6 months.
Trial: 16492824
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg sublingually 2 hours before surgery
Trial: 16492824
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg sublingually 10 minutes after surgery (Control)
Trial: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 200/100 mg
Trial: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400/100 mg
Trial: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400/200 mg
Trial: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) open-label 400/100 mg
Trial: 9007492
Drug: Budesonide (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (inhaled group, 100 micrograms qds) for 10 days
Trial: 3115153
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg . kg‐1)
Trial: 3115153
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with Alfentanil (2 mg . kg‐1 propofol with 4 micrograms . kg‐1 alfentanil)
Trial: 3115153
Drug: Ketamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine with Midazolam (0.5 mg . kg‐1 ketamine with 0.25 mg . kg‐1 midazolam)
Trial: 3115153
Drug: Ketamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine with Midazolam (1 mg . kg‐1 ketamine with 0.1 mg . kg‐1 midazolam)
Trial: 29685017
Drug: Posterior hemivertebra
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior hemivertebra resection in combination with screw rod internal fixation
Trial: 27010115
Drug: PPS 100
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPS 100 mg thrice daily
Trial: 27010115
Drug: PPS 100
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPS 100 mg once daily and placebo twice daily
Trial: 27010115
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin B complex tablet) thrice daily
Trial: 23874094
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg daily for 7 days
Trial: 10870071
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg/day orally for 4 days) after 3 days of intravenous ceftriaxone (100 mg/kg/day) and amikacin (15 mg/kg/day)
Trial: 9100553
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH; mean dose 2.4 IU daily)
Trial: 8096959
Drug: halofantrine (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: halofantrine (72 mg/kg)
Trial: 8096959
Drug: halofantrine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: halofantrine (24 mg/kg, 3 doses)
Trial: 8096959
Drug: mefloquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefloquine (25 mg/kg)
Trial: 3589701
Drug: continued interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continued interferon therapy
Trial: 30268528
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg/kg/h)
Trial: 17135784
Drug: Propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine hydrochloride immediate release (IR) 15 mg twice daily
Trial: 17135784
Drug: Propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine hydrochloride extended release (ER) 30 mg once daily
Trial: 31162005
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine only
Trial: 31162005
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus behavior change (cholera vaccine and handwashing plus drinking water chlorination promotion)
Trial: 31162005
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus behavior change
Trial: 31162005
Drug: Vaccine only
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine only
Trial: 25753159
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment protocol for gestational diabetes
Trial: 25753159
Drug: Regular method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular method of treatment for gestational diabetes
Trial: 20660131
Drug: 38 per
RxNorm normalized name: caffeine 38 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 per cent phosphoric acid gel
Trial: 20660131
Drug: 9.6 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.6 per cent hydrofluoric acid gel
Trial: 20660131
Drug: Control with
RxNorm normalized name: Azo Bladder Control With Go Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control with no surface treatment
Trial: 9213276
Drug: Thigh-high sequential
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh-high sequential pneumatic compression wraps